Newstral
Article
abqjournal.com on 2016-10-03 19:43
Updated: House panel: Mylan CEO minimized EpiPen profits in testimony
Related news
- House panel: Mylan CEO minimized EpiPen profits in testimonypost-gazette.com
- Mylan: Epipen profits higher than Bresch told Congresstriblive.com
- Mylan CEO set to defend EpiPen prices amid public outcrynewsobserver.com
- Mylan to pay $465M settlement over Medicaid EpiPen rebateskansascity.com
- Mylan to pay $465 million settlement over Medicaid EpiPen rebatesChicago Tribune
- Mylan CEO to testify in hearing on EpiPen price increasesdothaneagle.com
- MMylan CEO to answer for EpiPen price hikemoney.cnn.com
- Mylan CEO defends EpiPen pricesKHQ Local News
- Mylan investors push back over EpiPen maker’s executive salariesSan Jose Mercury News
- Mylan to Pay $465M Settlement Over Medicaid EpiPen Rebatesmemphisdailynews.com
- Mylan investors raise a fuss over EpiPen maker’s executive salariesSan Jose Mercury News
- Mylan profits, reputation at stake in EpiPen controversytriblive.com
- Last shot at EpiPen profits ends in Mylan monopolyThe Daily Gazette
- Mylan CEO: EpiPen $608 Price Was 'Fair'wsj.com
- EpiPen maker Mylan to restructure, cut workforcetriblive.com
- Mylan launching cheaper, generic version of EpiPenwbrc.com
- Mylan, US finalize $465M EpiPen settlementreviewjournal.com
- Mylan launching generic version of EpiPenwbrc.com